Alvotech Resolves Patent, Trade Secret Disputes With AbbVie

Alvotech secures U.S. rights for its proposed Humira biosimilar.

• Expects AVT02 (adalimumab) will be marketed in the U.S., subject to regulatory approval, on July 1, 2023
• All ongoing U.S. disputes between AbbVie and Alvotech have been resolved, including the ITC action brought forth in December
• NOTE: Dec. 7, Alvotech Going Public Through Oaktree SPAC Merger

NOTE

• AbbVie Inc. rose 0.0% in postmarket trading to $147.19 as of 5:10 p.m. New York time
  • The average 12-month price target of $152.55 is 3.6% above the current price
  • 18 buys, 7 holds, 1 sells

To view the source of this information, click here ...